Multimodal Molecular Imaging and Biometric Analysis in GBA-PD and Asymptomatic GBA-mutation Carriers
Status: Recruiting
Location: See all (3) locations...
Intervention Type: Diagnostic test
Study Type: Observational
SUMMARY
This study plans to analyze the molecular and clinical mechanisms of the relationship between the GBA mutations and Parkinson's disease. This will be assessed through the use of advanced neuroimaging techniques called PET (positron emission tomography) to study the accumulation of the tau protein and the dysfunction of acetylcholine and dopamine in the brain of people with a mutation in the GBA gene, with and without Parkinson's disease. The ingestigators will also use a technology-based assessment to study the typing patterns as possible biomarkers of early motor dysfunctions.
Eligibility
Participation Requirements
Sex: All
Minimum Age: 18
Maximum Age: 80
Healthy Volunteers: f
View:
• heterozygous for a pathogenic GBA mutation (e.g., p.L444P, p.N370S) or polymorphism;
• age 18 to 80 years.
Locations
United States
Oregon
Oregon Health & Science University
RECRUITING
Portland
Washington
University of Washington
RECRUITING
Seattle
Other Locations
Canada
Pacific Parkinson's Research Centre | University of British Columbia
RECRUITING
Vancouver
Contact Information
Primary
Jessamyn McKenzie
jess.mckenzie@ubc.ca
6048227764
Time Frame
Start Date: 2019-05-01
Estimated Completion Date: 2025-12-30
Participants
Target number of participants: 25
Treatments
GBA-PD
People with Parkinson's disease who are known heterozygous carriers of pathogenic GBA gene mutations.
Asymptomatic GBA
Known heterozygous carriers/obligated carriers of pathogenic GBA gene mutations.
Related Therapeutic Areas
Sponsors
Collaborators: Silverstein Foundation, University of Washington, Simon Fraser University, Weston Brain Institute, Oregon Health and Science University, Michael J. Fox Foundation for Parkinson's Research, University of British Columbia
Leads: Pacific Parkinson's Research Centre